1092 Results
Sort By:
Published on June 14, 2017
Trovagene said it will provide its Trovera urine ctDNA biomarker test and services to AstraZeneca, under an agreement whose value was not disclosed. Tovagene’s Trovera EGFR urine liquid biopsy test will initially be used in an open-label prospective biomarker study designed to evaluate whether the combination of noninvasive urine and…
Published on May 26, 2017
SomaGenics, a 20-year-old spinoff of nonprofit research organization SRI International has received a Phase 1 grant from the National Human Genome Research Institute (NHGRI), to develop a cell-free DNA (cfDNA) liquid biopsy platform, a tool for researchers to analyze and log single-stranded DNA fragments less than 100 nucleotides long. The…
Published on May 24, 2017
Terumo BCT said today it has joined the public-private European consortium seeking to establish standard protocols and clinical validation for blood-based cancer biomarkers. The consortium, CANCER-ID, will use Terumo BCT's Spectra Optia® Apheresis System in its research efforts aimed at assessing diagnostic leukapheresis (DLA) toward the capture and harvesting of…
Published on May 16, 2017
CANbridge Life Sciences will partner with Amoy Diagnostics (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was not disclosed. “We believe that the joint effort by CANbridge and AmoyDx could help to realize…
Published on May 8, 2017
A new study published in Cancer Epidemiology, Biomarkers & Prevention by a team of researchers from Yale, USC, UC San Diego, and Epic Sciences show the presence of PD-L1 protein on circulating cells from newly diagnosed lung cancer patient points to poor survival rates for patients not treated with a…
Published on April 27, 2017
Exact Sciences and MDxHealth have announced a five-year collaboration that will see the two companies share their respective epigenetic and diagnostics technologies with the aim of developing new epigenetic-based diagnostics across a range of indications including urology and lung cancer. “The collaboration may allow each party to better capitalize on…
Published on April 26, 2017
Molecular diagnostics accounts for only a tenth of the in vitro diagnostics (IVD) market—but most of its hopes for future revenue growth, according to Kalorama Information, which projects the MDx market will balloon to $10 billion by 2021. At 8% growth, molecular diagnostics is expected to double the 4% rate…
Published on April 17, 2017
HTG Molecular Diagnostics today announced a master services agreement with Daiichi Sankyo and a research agreement with France’s Centre Léon Bérard, both covering separate projects to develop targeted therapies. The value of the agreements was not disclosed. The agreement with Daiichi Sankyo covers several projects to be performed for the…
Published on April 14, 2017
An adapted CRISPR protein that targets RNA can serve as a rapid, inexpensive, and sensitive diagnostic tool say researchers from the Broad Institute of MIT and Harvard, the McGovern Institute for Brain Research at MIT, the Institute for Medical Engineering & Science at MIT, and the Wyss Institute for Biologically…
Published on April 6, 2017
Myriad Genetics said today it will partner with BeiGene to develop companion diagnostics for use with the biopharma’s novel poly ADP-ribose polymerase (PARP) inhibitor BGB-290, through a collaboration whose value was not disclosed. BeiGene has agreed to use Myriad’s myChoice HRD and BRACAnalysis CDx companion diagnostic tests to support the…
Published on April 3, 2017
Biocept said today it has granted Oregon Health & Sciences University (OHSU) rights to commercially offer the molecular diagnostics developer’s Target Selector™ liquid biopsy testing services exclusively throughout Oregon. In addition, OHSU can use Biocept’s Target Selector assays in-house, and serve as a secondary laboratory for Biocept's research and testing…
Published on March 30, 2017
The results from three news studies, all led by investigators at the University of Pennsylvania Perelman School of Medicine, are set to be presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting. The three studies focus on liquid biopsies, an innovation which uses blood tests instead of…
Published on March 22, 2017
Liquid biopsies in oncology initially focused on detecting and analyzing the numbers and types of circulating tumor cells (CTCs) in the blood, but more recently many researchers have come to include analysis of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA). cfDNA testing was first used in the United States…
Published on March 22, 2017
Estimates vary as much as the applications of technology when it comes to just how much the liquid biopsy market will grow over the next few years. During March alone, Market Research Future projected no less than a $450 billion market by 2022, based on CAGR of 21.6%, while RNCOS…
Published on March 22, 2017
It is likely one of the longest periods of foreshadowing in science. In 1869, Australian physician Thomas R. Ashworth first observed circulating tumor cells (CTCs) in one of his patients and suggested the treasure trove of information they might contain. “Cells identical with those of the cancer itself being seen in…